VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1520-1528

  Davidson, Ben ^a,b   Rosenfeld, Yifat B Z ^c   Holth, Arild ^a   Hellesylt, Ellen ^a   Tropé, Claes G ^a,b   Reich, Reuven ^c   Yisraeli, Joel K ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Effusions; Ovarian carcinoma; Survival; Tumor progression; VICKZ

Indexed keywords

ALPHA TUBULIN; GELATINASE B; MATRIGEL; PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VICKZ1 PROTEIN; VICKZ2 PROTEIN; VICKZ3 PROTEIN; VIRUS VECTOR;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EFFUSION; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; METASTASIS; MINIMAL RESIDUAL DISEASE; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE CULTURE; TUMOR BIOPSY; TUMOR INVASION; WESTERN BLOTTING; ZYMOGRAPHY;

EFFUSIONS; OVARIAN CARCINOMA; SURVIVAL; TUMOR PROGRESSION; VICKZ;

ADULT; AGED; ASCITIC FLUID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RNA-BINDING PROTEINS; SURVIVAL RATE;

EID: 84903219135     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.03.005     Document Type: Article

References (22)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
3. J.K. Yisraeli VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins Biol Cell 97 2005 87 96 (Pubitemid 40220715)
4. J.L. Bell, K. Wächter, and B. Mühleck et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70 2013 2657 2675
5. M. Köbel, D. Weidensdorfer, and C. Reinke et al. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma Oncogene 26 2007 7584 7589 (Pubitemid 350207710)
6. L. Gu, K. Shigemasa, and K. Ohama Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer Int J Oncol 24 2004 671 678
7. T. Takeuchi, Y. Ohishi, and H. Imamura et al. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma Am J Surg Pathol 37 2013 1091 1099
8. M. Köbel, H. Xu, and P.A. Bourne et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype Mod Pathol 22 2009 469 475
9. A. Noske, A. Faggad, and R. Wirtz et al. IMP3 expression in human ovarian cancer is associated with improved survival Int J Gynecol Pathol 28 2009 203 210
10. Y. Natkunam, G. Vainer, and J. Chen et al. Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms Haematologica 92 2007 176 183
11. F. Oberman, K. Rand, Y. Maizels, A.M. Rubinstein, and J.K. Yisraeli VICKZ proteins mediate cell migration via their RNA binding activity RNA 13 2007 1558 1569 (Pubitemid 47347426)
12. G. Vainer, E. Vainer-Mosse, and A. Pikarsky et al. A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation J Pathol 215 2008 445 456
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. I. Vergote, G.J. Rustin, and E.A. Eisenhauer et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534 1535
15. M.E. Schaner, B. Davidson, and M. Skrede et al. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients Mol Cancer 4 2005 26
16. O. Vaksman, T.H. Stavnes, J. Kærn, C.G. Trope, B. Davidson, and R. Reich miRNA profiling along tumor progression in ovarian carcinoma J Cell Mol Med 15 2011 1593 1602
17. X. Matias-Guiu, and B. Davidson Prognostic biomarkers in endometrial and ovarian carcinoma Virchows Arch 464 2014 315 331
18. B. Boyerinas, S.M. Park, and A.E. Murmann et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1 Int J Cancer 130 2012 1787 1797
19. N. Dai, J. Rapley, M. Angel, M.F. Yanik, M.D. Blower, and J. Avruch mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry Genes Dev 25 2011 1159 1172
20. N. Dai, J. Christiansen, F.C. Nielsen, and J. Avruch mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts Genes Dev 27 2013 301 312
21. M. Bunkholt Elstrand, H.P. Dong, and E. Edegaard et al. Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma Hum Pathol 41 2010 794 804
22. A. Slipicevic, G.F. Ey, and I.C. Askildt et al. The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions Hum Pathol 40 2009 527 537